132 related articles for article (PubMed ID: 18332900)
1. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.
Filopanti M; Barbieri AM; Angioni AR; Colao A; Gasco V; Grottoli S; Peri A; Baglioni S; Fustini MF; Pigliaru F; Monte PD; Borretta G; Ambrosi B; Jaffrain-Rea ML; Gasperi M; Brogioni S; Cannavò S; Mantovani G; Beck-Peccoz P; Lania A; Spada A
Pharmacogenomics J; 2008 Oct; 8(5):357-63. PubMed ID: 18332900
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.
Filopanti M; Lania AG; Spada A
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):43-53. PubMed ID: 19929252
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
Bueno C; Trarbach EB; Bronstein MD; Glezer A
Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
[TBL] [Abstract][Full Text] [Related]
4. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
[TBL] [Abstract][Full Text] [Related]
5. Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
Ilhan M; Kahraman OT; Turan S; Turgut S; Karaman O; Zeybek U; Shukurov S; Yaylim I; Tasan E
Ann Endocrinol (Paris); 2015 Oct; 76(5):614-9. PubMed ID: 26514951
[TBL] [Abstract][Full Text] [Related]
6. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
7. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma.
Lombardi M; Lupi I; Cosottini M; Rossi G; Manetti L; Raffaelli V; Sardella C; Martino E; Bogazzi F
Horm Metab Res; 2014 Dec; 46(13):939-42. PubMed ID: 25230324
[TBL] [Abstract][Full Text] [Related]
8. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
Cannavò S; Bartolone L; Blandino A; Spinella S; Galatioto S; Trimarchi F
J Endocrinol Invest; 1999 Apr; 22(4):306-9. PubMed ID: 10342366
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the DRD2 gene haplotype and its association with alcoholism in Mexican Americans.
Luo HR; Hou ZF; Wu J; Zhang YP; Wan YJ
Alcohol; 2005 Jun; 36(2):117-25. PubMed ID: 16396745
[TBL] [Abstract][Full Text] [Related]
10. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors.
Friedman E; Adams EF; Höög A; Gejman PV; Carson E; Larsson C; De Marco L; Werner S; Fahlbusch R; Nordenskjöld M
J Clin Endocrinol Metab; 1994 Mar; 78(3):568-74. PubMed ID: 7907340
[TBL] [Abstract][Full Text] [Related]
11. A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence.
Han DH; Yoon SJ; Sung YH; Lee YS; Kee BS; Lyoo IK; Renshaw PF; Cho SC
Compr Psychiatry; 2008; 49(4):387-92. PubMed ID: 18555060
[TBL] [Abstract][Full Text] [Related]
12. DRD2/ANKK1 TaqI polymorphism and smoking behavior of Egyptian male cigarette smokers.
Radwan GN; El-Setouhy M; Mohamed MK; Hamid MA; Azem SA; Kamel O; Israel E; Loffredo CA
Nicotine Tob Res; 2007 Dec; 9(12):1325-9. PubMed ID: 18058350
[TBL] [Abstract][Full Text] [Related]
13. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
[TBL] [Abstract][Full Text] [Related]
14. Linkage and association of DRD2 gene TaqI polymorphism with schizophrenia in an Iranian population.
Behravan J; Hemayatkar M; Toufani H; Abdollahian E
Arch Iran Med; 2008 May; 11(3):252-6. PubMed ID: 18426314
[TBL] [Abstract][Full Text] [Related]
15. Ultrastructural morphometry of prolactin secreting adenomas treated with dopamine agonists.
Schottke H; Saeger W; Lüdecke DK; Caselitz J
Pathol Res Pract; 1986 Jun; 181(3):280-90. PubMed ID: 3748874
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
[TBL] [Abstract][Full Text] [Related]
17. The taqI DRD2 A1 allele is associated with alcohol-dependence although its effect size is small.
Berggren U; Fahlke C; Aronsson E; Karanti A; Eriksson M; Blennow K; Thelle D; Zetterberg H; Balldin J
Alcohol Alcohol; 2006; 41(5):479-85. PubMed ID: 16751215
[TBL] [Abstract][Full Text] [Related]
18. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
19. Analysis of dopamine D2 receptor (DRD2) gene polymorphisms in cannabinoid addicts.
Nacak M; Isir AB; Balci SO; Pehlivan S; Benlier N; Aynacioglu S
J Forensic Sci; 2012 Nov; 57(6):1621-4. PubMed ID: 22536882
[TBL] [Abstract][Full Text] [Related]
20. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
